Successful combination treatment of clofarabine, cytarabine and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia
Résumé
Despite relevant advances in survival rates of pediatric acute lymphoblastic leukemia (ALL), in adult patients the outcome is still dismal, due to a greater drug resistance, a poorer compliance with treatment, and less effective current therapies. The need for more active agents has identified a novel purine nucleoside analogue, clofarabine, which has been approved for the treatment of children with relapsed and refractory ALL, showing also promising clinical benefit in phase I-II studies in adult patients.
Origine : Fichiers produits par l'(les) auteur(s)